USA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years in young adults, according to surgeons at Yale Medicine. As well, there are now alarming reports around...
In this article, discover how low beta stocks can shimmer in your portfolio!
TScan Therapeutics, Inc. (TCRX) delivered earnings and revenue surprises of -27.40% and 119.52%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...
TScan Therapeutics, Inc. (NASDAQ: TCRX) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development
/PRNewswire/ -- Amgen (NASDAQ:AMGN) and TScan Therapeutics, Inc. (NASDAQ:TCRX), today announced a multi-year collaboration that will use TScan's proprietary...
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of -27.45% and 37.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...
Phase 1 umbrella trial for hematologic malignancies open for enrollment Publication in Cell further validates use of foundational technology to identify...
Lumos (LUMO) delivered earnings and revenue surprises of 4.08% and 266.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
WALTHAM, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...
TScan screening technology used to identify the targets of expanded T cell clones in the tumors of patients with head and neck cancer responding to...